| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Molecular and Cellular Biology, and
Microchemistry Facility, Harvard University, Cambridge, MA 02138;
Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; and
§
Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
Copolymer 1 (Cop 1, poly (Y, E, A, K)) is a random synthetic amino acid copolymer effective in the treatment of relapsing forms of multiple sclerosis (MS). Cop 1 binds promiscuously, with high affinity and in a peptide-specific manner to purified MS-associated HLA-DR2 (DRB1*1501) and rheumatoid arthritis-associated HLA-DR1 (DRB1*0101) or HLA-DR4 (DRB1*0401) molecules. In the present work at least 95% of added Cop 1 could be bound to recombinant "empty" HLA-DR1 and -DR4, and 80% could be bound to HLA-DR2 proteins. Amino acid composition, HPLC profiles, and sequencing patterns of Cop 1 eluted by acid extraction from HLA-DR molecules were similar to those of the unseparated Cop 1. Protruding N-terminal ends of Cop 1 bound to HLA-DR1, -DR2, or -DR4 molecules were then treated with aminopeptidase I, followed by elution, HPLC, and pool sequencing. In contrast to untreated or unbound Cop 1, this material exhibited distinct motifs at some positions with increases in levels of E at the first and second cycles, of K at the second and third cycles, and of Y (presumably at P1 of the bound peptide) at the third to fifth cycles, regardless of the HLA-DR molecule employed. No preference was seen at the following cycles that were mainly A. These first pooled HLA-DR binding epitopes provide clues to the components of Cop 1 that are biologically active in suppressing MS and possibly rheumatoid arthritis.
This article has been cited by other articles:
|
|
 |
|
  R.M. Valenzuela, K. Costello, M. Chen, A. Said, K.P. Johnson, and S. Dhib-Jalbut Clinical response to glatiramer acetate correlates with modulation of IFN-{gamma} and IL-4 expression in multiple sclerosis Multiple Sclerosis, July 1, 2007; 13(6): 754 - 762. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Horani, N. Muhanna, O. Pappo, A. Melhem, C. E. Alvarez, S. Doron, W. Wehbi, K. Dimitrios, S. L. Friedman, and R. Safadi Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis Am J Physiol Gastrointest Liver Physiol, February 1, 2007; 292(2): G628 - G638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Tennakoon, R. S. Mehta, S. B. Ortega, V. Bhoj, M. K. Racke, and N. J. Karandikar Therapeutic Induction of Regulatory, Cytotoxic CD8+ T Cells in Multiple Sclerosis. J. Immunol., June 1, 2006; 176(11): 7119 - 7129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hong, N. Li, X. Zhang, B. Zheng, and J. Z. Zhang Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3 PNAS, May 3, 2005; 102(18): 6449 - 6454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. H. Stern, Z. Illes, J. Reddy, D. B. Keskin, M. Fridkis-Hareli, V. K. Kuchroo, and J. L. Strominger Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis PNAS, February 1, 2005; 102(5): 1620 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sela and E. Mozes Therapeutic vaccines in autoimmunity PNAS, October 5, 2004; 101(suppl_2): 14586 - 14592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Illes, J. N. H. Stern, J. Reddy, H. Waldner, M. P. Mycko, C. F. Brosnan, S. Ellmerich, D. M. Altmann, L. Santambrogio, J. L. Strominger, et al. Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells PNAS, August 10, 2004; 101(32): 11749 - 11754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Y. Arnold, N. L. La Gruta, T. Miller, K. M. Vignali, P. S. Adams, D. L. Woodland, and D. A. A. Vignali The Majority of Immunogenic Epitopes Generate CD4+ T Cells That Are Dependent on MHC Class II-Bound Peptide-Flanking Residues J. Immunol., July 15, 2002; 169(2): 739 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Fusco, V. Andreone, G. Coppola, V. Luongo, F. Guerini, E. Pace, C. Florio, G. Pirozzi, R. Lanzillo, P. Ferrante, et al. HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis Neurology, December 11, 2001; 57(11): 1976 - 1979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Ruiz, J. J. DeVoss, L.-V. T. Nguyen, P. P. Fontoura, D. L. Hirschberg, D. J. Mitchell, K. C. Garcia, and L. Steinman Immunomodulation of Experimental Autoimmune Encephalomyelitis with Ordered Peptides Based on MHC-TCR Binding Motifs J. Immunol., September 1, 2001; 167(5): 2688 - 2693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Davidson and B. Diamond Autoimmune Diseases N. Engl. J. Med., August 2, 2001; 345(5): 340 - 350. [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. McNeel, L. D. Nguyen, and M. L. Disis Identification of T Helper Epitopes from Prostatic Acid Phosphatase Cancer Res., July 1, 2001; 61(13): 5161 - 5167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Neuhaus, C. Farina, H. Wekerle, and R. Hohlfeld Mechanisms of action of glatiramer acetate in multiple sclerosis Neurology, March 27, 2001; 56(6): 702 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Duda, J. I. Krieger, M. C. Schmied, C. Balentine, and D. A. Hafler Human and Murine CD4 T Cell Reactivity to a Complex Antigen: Recognition of the Synthetic Random Polypeptide Glatiramer Acetate J. Immunol., December 15, 2000; 165(12): 7300 - 7307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Neuhaus, C. Farina, A. Yassouridis, H. Wiendl, F. Then Bergh, T. Dose, H. Wekerle, and R. Hohlfeld Multiple sclerosis: Comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells PNAS, June 20, 2000; 97(13): 7452 - 7457. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
